96. Crohn disease Clinical trials / Disease details
Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2010-022215-19-GB (EUCTR) | 21/07/2011 | 23/06/2011 | Combined growth hormone and IGF1 therapy in paediatric Crohn'd disease | A Pharmacokinetic Study Of The Combined Use Of Recombinant Human GH And IGF-1 In Children With Inflammatory Bowel (Crohn’s) Disease - Combination rhGH + rhIGF-1 in childhood/adolescent Crohn’s | Impaired growth in Paediatric Crohn's disease MedDRA version: 14.1;Level: LLT;Classification code 10011398;Term: Crohn's;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Trade Name: Increlex Product Name: Increlex 10mg/ml solution for injection INN or Proposed INN: Mecasermin [rDNA Origin] 10mg/ml solution Other descriptive name: Recombinant human Insulin-like Growth Factor Trade Name: NutropinAq® Product Name: NutropinAq 10mg/2ml solution for injection INN or Proposed INN: Somatropin(rhGH) Other descriptive name: recombinant growth hormone | Greater Glasgow & Clyde NHS | NULL | Not Recruiting | Female: yes Male: yes | 24 | Phase 2 | United Kingdom | ||
| 2 | NCT00764699 (ClinicalTrials.gov) | October 2008 | 1/10/2008 | Effect of Increlex® on Children With Crohn Disease | Effect of Increlex® on Children With Crohn Disease | Crohn Disease | Drug: rhIGF (Increlex) | Nationwide Children's Hospital | Tercica | Terminated | 5 Years | 15 Years | All | 3 | Phase 2/Phase 3 | United States |
| 3 | EUCTR2007-004269-16-GB (EUCTR) | 28/02/2008 | 26/03/2008 | Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I) in children with Crohn’s disease-induced growth retardation. - IGF-I in growth-retarded Crohn's disease children | Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I) in children with Crohn’s disease-induced growth retardation. - IGF-I in growth-retarded Crohn's disease children | Growth failure in children with Crohn's disease | Trade Name: Increlex Product Name: Increlex 10mg/ml solution for injection | Queen Mary, University of London | NULL | Not Recruiting | Female: yes Male: yes | United Kingdom |